XXXX therapy improved left ventricular function in a @entity1 with arrhythmogenic right ventricular cardiomyopathy.

@entity1 @entity296 @entity1165 @entity714 @entity944 @entity1347 @entity1405 @entity439 @entity3044 @entity943
An asymptomatic 35 year-old @entity1 was referred to our hospital because of abnormal ECG findings. The ECG showed complete @entity714 and @entity1347 . Echocardiography revealed a moderately enlarged right ventricle (RV) and an apical @entity439 . RV wall motion showed diffusely moderate impairment, while the systolic function of the left ventricle (LV) was slightly decreased. The ejection fractions (EF) of the RV and LV were calculated as 28.1% and 41.9% by Simpson's method using multiple cardiac computed tomography (CT) scans. A 24 hour ambulatory ECG showed only 372 single premature ventricular contractions (PVC). Cardiac catheterizaion revealed that the RV was enlarged with prominent trabeculation and decreased motion. In an electrophysiologic study, neither electrical stimulation of the RV nor electrical stimulation plus @entity3044 infusion could induce @entity1165 . Pathological examination of a biopsy from the interventricular septum of the RV revealed fibrofatty change in the myocardium. Based on these results, we made a diagnosis of @entity296 ( @entity296 ) and administered 5 mg of @entity1405 . Sixty days after the initiation of @entity1405 therapy, we performed repeat cardiac CT. The EF of the LV was markedly improved from 41.9% to 62.0%, although the EF of the RV was not changed. The number of PVCs showed no change. This case suggests that @entity1405 is not only useful for controlling @entity943 but also for improving left ventriclular function in some @entity1 with @entity296 . Sympathetic overactivity is reported to cause @entity944 , so @entity1405 may be a first-line drug for some @entity1 with @entity296 .
